InSilico Medicine

Insilico Medicine is a clinical-stage biotechnology company using generative artificial intelligence to accelerate drug discovery and development. Founded in 2014, the company has built an end-to-end AI platform that applies machine learning across biology, chemistry, and clinical development to identify novel therapeutic targets, design new molecules, and advance drug candidates toward the clinic.

Its proprietary Pharma.AI platform combines tools for target discovery, generative chemistry, and clinical development and supports both Insilico’s internal drug pipeline and collaborations with pharmaceutical and biotechnology companies. The company has developed a broad pipeline across fibrosis, oncology, immunology, and other diseases, and was responsible for advancing the first drug both discovered and designed using generative AI into human clinical trials.